Search

Displaying results 6051 - 6060 of 8694 in total
  1. Drug

    Serlopitant

    go.drugbank.com/drugs/DB12973
    Investigational

    Serlopitant has been investigated for the treatment of Prurigo Nodularis.

    Categories: Neurokinin-1 Receptor Antagonists
  2. Drug

    CGX-1321

    go.drugbank.com/drugs/DB17491
    Investigational

    CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling.[A257038]

  3. Drug

    Camidanlumab tesirine

    go.drugbank.com/drugs/DB16411
    Investigational

    Camidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).

  4. Drug

    Myrrh

    go.drugbank.com/drugs/DB11605
    ApprovedInvestigational

    Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.

  5. Drug

    Canertinib

    go.drugbank.com/drugs/DB05424
    Investigational

    Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo.

  6. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    While the primary components of cannabis, CBD and THC, have been shown to modulate many of their physiological effects through their binding to the cannabinoid-1 (CB1R) and cannabinoid-2 (CB2R) receptors … In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951].

  7. Drug

    Cenplacel-L

    go.drugbank.com/drugs/DB19188
    Investigational

    Cenplacel-L is under investigation in clinical trial (Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke) for the treatment of patients

  8. Drug

    CPD 923

    go.drugbank.com/drugs/DB05856
    Experimental

    CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

  9. Drug

    SPP1148

    go.drugbank.com/drugs/DB05203
    Experimental

    SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.

  10. Drug

    LY-2599506

    go.drugbank.com/drugs/DB05970
    Investigational

    LY2599506 was under investigation in clinical trials NCT01024244 and NCT01029795 for the treatment of patients with type 2 diabetes.